86.45
+0.12%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Innovent Biologics
Its shares trade on HKEX under the ticker 1801.HK. It has been listed since 31 October 2018. In the fiscal year to 31 December 2025, it reported revenue of CN¥15.18bn and net income of CN¥946.8m. At that date it held total assets of CN¥43.48bn and shareholders' equity of CN¥22.54bn.
Innovent Biologics, Inc. is an investment company, which engages in the development and manufacture of biopharmaceutical products. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2018-10-31. The firm and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The firm's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The firm's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 31 Oct 2018
- Employees
- 1,982
- Website
- innoventbio.com ↗
Leadership
Pay as last reported
- Dr. De-Chao YuExecutive Chairman of the Board, Chief Executive Officer, since 2011CN¥36.4m
- Ms. You FeiChief Financial Officer
- Mr. Hao Xi EdeExecutive Director, since 2018CN¥7.1m
- Ms. Qian ZhangExecutive Director, since 2024
- Ms. Lok Yee ChanJoint Company Secretary
- Ms. Yanju WangJoint Company Secretary
- Mr. Shuyun ChenIndependent Non-Executive DirectorCN¥360,000
- Dr. Charles CooneyNon-Executive Independent DirectorCN¥400,000
- Mr. Zieziula GaryNon-Executive Independent DirectorCN¥400,000
- Ms. I-Yin HsuNon-Executive Independent DirectorCN¥400,000
- Dr. Lu ShunNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 76
- Environment
- 98
- Social
- 99
- Governance
- 31
- Direct emissions (scope 1)
- 65.17 t
- Energy emissions (scope 2)
- 15,829.25 t
- Women in the workforce
- 50.22578%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong Research and Development Capabilities: Innovent Biologics Inc has a solid R&D team that is capable of developing innovative and high-quality biologic drugs.
- Strategic Partnerships: The company has established strategic partnerships with leading pharmaceutical companies, which provide access to resources and expertise, enhancing its competitive advantage.
- Robust Product Pipeline: Innovent Biologics Inc has a diverse and promising pipeline of biologic drugs, which ensures future growth opportunities and potential revenue streams.
Weaknesses
- Dependency on Partnerships: While partnerships are a strength, heavy reliance on them can also be a weakness, as the success and timing of collaborative projects may be beyond the company's control.
- Limited Market Presence: Innovent Biologics Inc is relatively new in the biopharmaceutical industry, which limits its brand recognition and market penetration compared to established competitors.
- Regulatory Challenges: The company needs to navigate complex regulatory processes for drug approvals, which can be time-consuming and costly, potentially delaying market entry.
Opportunities
- Growing Biopharmaceutical Market: The increasing demand for biologic drugs presents a significant opportunity for Innovent Biologics Inc to capture a larger market share and generate higher revenues.
- Expansion into International Markets: The company can explore expansion opportunities in untapped international markets, leveraging its expertise and partnerships to enter new regions.
- Strategic Collaborations: Innovent Biologics Inc can seek further collaborations with academic institutions, research organizations, and industry players to enhance technology, knowledge sharing, and product development.
Threats
- Intense Competition: The biopharmaceutical industry is highly competitive, with many established players and emerging companies. Innovent Biologics Inc faces the risk of increased competition, which may impact its market share and pricing power.
- Intellectual Property Risks: Protecting intellectual property is crucial for biopharmaceutical companies. Innovent Biologics Inc faces the threat of patent infringement lawsuits or unauthorized use of its proprietary technologies, potentially harming its business.
- Regulatory and Compliance Risks: Changes in regulatory requirements or non-compliance with existing regulations can pose challenges for drug development and commercialization, leading to delays or restrictions on product offerings.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.